Abiopharma

New Form 144 - INSULET CORP Filed: 2025-08-07 AccNo: 0001959173-25-005006 Size: 5 KB

New Form 8-K - AMEDISYS INC Filed: 2025-08-07 AccNo: 0001193125-25-175190 Size: 147 KB Item 8.01: Other Events

New Form SCHEDULE 13G/A - Beam Therapeutics Inc. Filed: 2025-08-07 AccNo: 0001104659-25-075081 Size: 13 KB

Smith+Nephew PLC Notification

New Form SCHEDULE 13G - Semler Scientific, Inc. Filed: 2025-08-07 AccNo: 0000895421-25-000478 Size: 11 KB

Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results

New Form 144 - RESMED INC Filed: 2025-08-07 AccNo: 0001959173-25-005004 Size: 6 KB

New SEC Form for ResMed Inc.

Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

Genmab Announces Financial Results for the First Half of 2025

New Form SCHEDULE 13G/A - Dyne Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001274173-25-000196 Size: 9 KB

New Form SCHEDULE 13G/A - Travere Therapeutics, Inc. Filed: 2025-08-07 AccNo: 0001274173-25-000194 Size: 9 KB

New Form SCHEDULE 13G/A - Avidity Biosciences, Inc. Filed: 2025-08-07 AccNo: 0001274173-25-000195 Size: 9 KB

New Form 6-K - GENMAB A/S Filed: 2025-08-07 AccNo: 0001434265-25-000061 Size: 131 KB

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)